Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study

Disease Sites:

Breast

Staging:

Phase III

Age Group:

Adults

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Abramson, Vandana

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

06-25-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTBRE24171

National Clinical Trial ID:

NCT06492616

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available